메뉴 건너뛰기




Volumn 1, Issue 2, 2007, Pages 121-127

Nilotinib: A novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Author keywords

Chronic myeloid leukemia; Imatinib resistance; Nilotinib

Indexed keywords


EID: 79955866504     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (14)

References (50)
  • 1
    • 10244257546 scopus 로고    scopus 로고
    • Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
    • Baccarani M, Martinelli G, Rosti G, et al. 2004. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood, 104:4245-51.
    • (2004) Blood , vol.104 , pp. 4245-4251
    • Baccarani, M.1    Martinelli, G.2    Rosti, G.3
  • 2
    • 33747154547 scopus 로고    scopus 로고
    • Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
    • Baccarani M, Saglio G, Goldman J, et al. 2006. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108:1809-20.
    • (2006) Blood , vol.108 , pp. 1809-1820
    • Baccarani, M.1    Saglio, G.2    Goldman, J.3
  • 3
    • 33645464074 scopus 로고    scopus 로고
    • Detection of BCR-ABL mutations and resistance to imatinib mesylate
    • Branford S, Hughes T. 2006. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med, 125:93-106.
    • (2006) Methods Mol Med , vol.125 , pp. 93-106
    • Branford, S.1    Hughes, T.2
  • 4
    • 0036566540 scopus 로고    scopus 로고
    • High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
    • Branford S, Rudzki Z, Walsh S, et al. 2002. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99:3472-5.
    • (2002) Blood , vol.99 , pp. 3472-3475
    • Branford, S.1    Rudzki, Z.2    Walsh, S.3
  • 5
    • 10744232328 scopus 로고    scopus 로고
    • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
    • Branford S, Rudzki Z, Walsh, et al. 2003. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 102:276-83.
    • (2003) Blood , vol.102 , pp. 276-283
    • Branford, S.1    Rudzki, Z.2    Walsh3
  • 6
    • 23344440655 scopus 로고    scopus 로고
    • Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
    • Carter TA, Wodicka LM, Shah, et al. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA, 102:11011-16.
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 11011-11016
    • Carter, T.A.1    Wodicka, L.M.2    Shah3
  • 7
    • 33644532202 scopus 로고    scopus 로고
    • SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling
    • Coluccia AM, Benati D, Dekhil, et al. 2006. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res, 66:2279-86.
    • (2006) Cancer Res , vol.66 , pp. 2279-2286
    • Coluccia, A.M.1    Benati, D.2    Dekhil3
  • 8
    • 33947356135 scopus 로고    scopus 로고
    • Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in blast crisis
    • Cortes J, Rousselot P, Kim DW, et al. 2007. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109:3207-13.
    • (2007) Blood , vol.109 , pp. 3207-3213
    • Cortes, J.1    Rousselot, P.2    Kim, D.W.3
  • 9
    • 2342629325 scopus 로고    scopus 로고
    • Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment
    • Cowan-Jacob SW, Guez V, Fendrich G, et al. 2004. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem, 4:285-99.
    • (2004) Mini Rev Med Chem , vol.4 , pp. 285-299
    • Cowan-Jacob, S.W.1    Guez, V.2    Fendrich, G.3
  • 10
    • 33845444046 scopus 로고    scopus 로고
    • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    • Druker BJ, Guilhot F, O'Brien SG, et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355:2408-17.
    • (2006) N Engl J Med , vol.355 , pp. 2408-2417
    • Druker, B.J.1    Guilhot, F.2    O'Brien, S.G.3
  • 11
    • 0035810147 scopus 로고    scopus 로고
    • Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
    • Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344:1031-7.
    • (2001) N Engl J Med , vol.344 , pp. 1031-1037
    • Druker, B.J.1    Talpaz, M.2    Resta, D.J.3
  • 12
    • 34247380370 scopus 로고    scopus 로고
    • A phase II study of Nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy
    • Giles F, le Coutre P, Bhalla B, et al. 2006. A phase II study of Nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy. Blood (ASH Annual Meeting Abstracts), 108:2170.
    • (2006) Blood (ASH Annual Meeting Abstracts) , vol.108 , pp. 2170
    • Giles, F.1    Coutre, P.2    Bhalla, B.3
  • 13
    • 33846240316 scopus 로고    scopus 로고
    • MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
    • Giles FJ, Cortes J, Jones D, et al. 2007. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood, 109:500-2.
    • (2007) Blood , vol.109 , pp. 500-502
    • Giles, F.J.1    Cortes, J.2    Jones, D.3
  • 14
    • 20444500171 scopus 로고    scopus 로고
    • SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models
    • Golas JM, Lucas J, Etienne C, et al. 2005. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res, 65:5358-64.
    • (2005) Cancer Res , vol.65 , pp. 5358-5364
    • Golas, J.M.1    Lucas, J.2    Etienne, C.3
  • 15
    • 30844457497 scopus 로고    scopus 로고
    • Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: Does it really matter?
    • Goldman J, Gordon M. 2006. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma, 47:1-7.
    • (2006) Leuk Lymphoma , vol.47 , pp. 1-7
    • Goldman, J.1    Gordon, M.2
  • 16
    • 24644435728 scopus 로고    scopus 로고
    • AMN107, a novel amino- pyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
    • Golemovic M, Verstovsek S, Giles F, et al. 2005. AMN107, a novel amino- pyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res, 11:4941-7.
    • (2005) Clin Cancer Res , vol.11 , pp. 4941-4947
    • Golemovic, M.1    Verstovsek, S.2    Giles, F.3
  • 17
    • 13844261144 scopus 로고    scopus 로고
    • A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
    • Gumireddy K, Baker SJ, Cosenza SC, et al. 2005. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA, 102:1992-7.
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 1992-1997
    • Gumireddy, K.1    Baker, S.J.2    Cosenza, S.C.3
  • 18
    • 0038700994 scopus 로고    scopus 로고
    • Cytogenetic and molecular mechanisms of resistance to imatinib
    • Hochhaus A. 2003. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol, 40:69-79.
    • (2003) Semin Hematol , vol.40 , pp. 69-79
    • Hochhaus, A.1
  • 19
    • 33947280081 scopus 로고    scopus 로고
    • Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy
    • Hochhaus A, Kantarjian HM, Baccarani M, et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109:2303-9.
    • (2007) Blood , vol.109 , pp. 2303-2309
    • Hochhaus, A.1    Kantarjian, H.M.2    Baccarani, M.3
  • 20
    • 0036850514 scopus 로고    scopus 로고
    • Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
    • Hochhaus A, Kreil S, Corbin AS, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16:2190-6.
    • (2002) Leukemia , vol.16 , pp. 2190-2196
    • Hochhaus, A.1    Kreil, S.2    Corbin, A.S.3
  • 21
    • 10744229080 scopus 로고    scopus 로고
    • Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    • Hughes TP, Kaeda J, Branford S, et al. 2003. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 349:1423-32.
    • (2003) N Engl J Med , vol.349 , pp. 1423-1432
    • Hughes, T.P.1    Kaeda, J.2    Branford, S.3
  • 22
    • 33644838303 scopus 로고    scopus 로고
    • Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
    • Iacobucci I, Rosti G, Amabile M, et al. 2006. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol, 24:454-9.
    • (2006) J Clin Oncol , vol.24 , pp. 454-459
    • Iacobucci, I.1    Rosti, G.2    Amabile, M.3
  • 23
    • 34247403450 scopus 로고    scopus 로고
    • Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP)
    • Jabbour E, Cortes J, Giles F, et al. 2006. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Blood (ASH Annual Meeting Abstracts), 108:2172.
    • (2006) Blood (ASH Annual Meeting Abstracts) , vol.108 , pp. 2172
    • Jabbour, E.1    Cortes, J.2    Giles, F.3
  • 24
    • 33745086350 scopus 로고    scopus 로고
    • Nilotinib in imatinib- resistant CML and Philadelphia chromosome-positive ALL
    • Kantarjian H, Giles F, Wunderle L, et al. 2006a. Nilotinib in imatinib- resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354:2542-51.
    • (2006) N Engl J Med , vol.354 , pp. 2542-2551
    • Kantarjian, H.1    Giles, F.2    Wunderle, L.3
  • 25
    • 4644359704 scopus 로고    scopus 로고
    • Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon- alpha
    • Kantarjian HM, Cortes JE, O'Brien S, et al. 2004. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon- alpha. Blood, 104:1979-88.
    • (2004) Blood , vol.104 , pp. 1979-1988
    • Kantarjian, H.M.1    Cortes, J.E.2    O'Brien, S.3
  • 26
    • 33846812048 scopus 로고    scopus 로고
    • A phase ii study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
    • Kantarjian HM, Gattermann N, Hochhaus A, et al. 2006b. A phase ii study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). Blood (ASH Annual Meeting Abstracts), 108:2169.
    • (2006) Blood (ASH Annual Meeting Abstracts) , vol.108 , pp. 2169
    • Kantarjian, H.M.1    Gattermann, N.2    Hochhaus, A.3
  • 27
    • 33748696341 scopus 로고    scopus 로고
    • Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
    • Kantarjian HM, Talpaz M, O'Brien S, et al. 2006c. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood, 108:1835-40.
    • (2006) Blood , vol.108 , pp. 1835-1840
    • Kantarjian, H.M.1    Talpaz, M.2    O'Brien, S.3
  • 28
    • 22044442973 scopus 로고    scopus 로고
    • Tyrosine kinases as targets for cancer therapy
    • Krause DS, Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. N Engl J Med, 353:172-87.
    • (2005) N Engl J Med , vol.353 , pp. 172-187
    • Krause, D.S.1    van Etten, R.A.2
  • 29
    • 33846814283 scopus 로고    scopus 로고
    • A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    • le Coutre P, Bhalla K, Giles F, et al. 2006. A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Blood (ASH Annual Meeting Abstracts), 108:165.
    • (2006) Blood (ASH Annual Meeting Abstracts) , vol.108 , pp. 165
    • Coutre, P.1    Bhalla, K.2    Giles, F.3
  • 30
    • 33845723163 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) pharma-cokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
    • Luo FR, Yang Z, Camuso A, et al. 2006. Dasatinib (BMS-354825) pharma-cokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res, 12:7180-6.
    • (2006) Clin Cancer Res , vol.12 , pp. 7180-7186
    • Luo, F.R.1    Yang, Z.2    Camuso, A.3
  • 31
    • 33645509358 scopus 로고    scopus 로고
    • Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple- quadrupole and linear ion trap mass spectrometers
    • Marull M, Rochat B. 2006. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple- quadrupole and linear ion trap mass spectrometers. J Mass Spectrom, 41:390-404.
    • (2006) J Mass Spectrom , vol.41 , pp. 390-404
    • Marull, M.1    Rochat, B.2
  • 33
    • 0037079720 scopus 로고    scopus 로고
    • Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
    • Mow BM, Chandra J, Svingen PA, et al. 2002. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood, 99:664-71.
    • (2002) Blood , vol.99 , pp. 664-671
    • Mow, B.M.1    Chandra, J.2    Svingen, P.A.3
  • 34
    • 9144253153 scopus 로고    scopus 로고
    • Dynamics of BCR- ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
    • Muller MC, Gattermann N, Lahaye T, et al. 2003. Dynamics of BCR- ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 17:2392-400.
    • (2003) Leukemia , vol.17 , pp. 2392-2400
    • Muller, M.C.1    Gattermann, N.2    Lahaye, T.3
  • 35
    • 0037762632 scopus 로고    scopus 로고
    • Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien SG, Deininger MW. 2003. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol, 40:26-30.
    • (2003) Semin Hematol , vol.40 , pp. 26-30
    • O'Brien, S.G.1    Deininger, M.W.2
  • 36
    • 30644462841 scopus 로고    scopus 로고
    • Targeted CML therapy: Controlling drug resistance, seeking cure
    • O'Hare T, Corbin AS, Druker BJ. 2006. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev, 16:92-9.
    • (2006) Curr Opin Genet Dev , vol.16 , pp. 92-99
    • O'Hare, T.1    Corbin, A.S.2    Druker, B.J.3
  • 37
    • 21144451094 scopus 로고    scopus 로고
    • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    • O'Hare T, Walters DK, Stoffregen EP, et al. 2005. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65:4500-5.
    • (2005) Cancer Res , vol.65 , pp. 4500-4505
    • O'Hare, T.1    Walters, D.K.2    Stoffregen, E.P.3
  • 38
    • 33750479897 scopus 로고    scopus 로고
    • Successful mobilization of Ph-negative blood stem cells with intensive chemo-therapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase
    • Olsson-Stromberg U, Hoglund M, Bjorkholm M, et al. 2006. Successful mobilization of Ph-negative blood stem cells with intensive chemo-therapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma, 47:1768-73.
    • (2006) Leuk Lymphoma , vol.47 , pp. 1768-1773
    • Olsson-Stromberg, U.1    Hoglund, M.2    Bjorkholm, M.3
  • 39
    • 34247338940 scopus 로고    scopus 로고
    • A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL)
    • Ottmann O, Kantarjian H, Larson R, et al. 2006. A phase ii study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 108:1862.
    • (2006) Blood (ASH Annual Meeting Abstracts) , vol.108 , pp. 1862
    • Ottmann, O.1    Kantarjian, H.2    Larson, R.3
  • 40
    • 23844553757 scopus 로고    scopus 로고
    • T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: Insights from a computational study
    • Pricl S, Fermeglia M, Ferrone, et al. 2005. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol Cancer Ther, 4:1167-74.
    • (2005) Mol Cancer Ther , vol.4 , pp. 1167-1174
    • Pricl, S.1    Fermeglia, M.2    Ferrone3
  • 41
    • 33846200681 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
    • Quintas-Cardama A, Kantarjian H, et al. 2007. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 109:497-9.
    • (2007) Blood , vol.109 , pp. 497-499
    • Quintas-Cardama, A.1    Kantarjian, H.2
  • 42
    • 79959308232 scopus 로고    scopus 로고
    • Loss of response to imatinib: Mechanisms and management
    • Shah NP. 2005. Loss of response to imatinib: mechanisms and management. Hematology (Am Soc Hematol Educ Program), 183-7.
    • (2005) Hematology (Am Soc Hematol Educ Program) , pp. 183-187
    • Shah, N.P.1
  • 43
    • 33845254606 scopus 로고    scopus 로고
    • Improving upon the promise of targeted therapy of human malignancy: Chronic myeloid leukemia as a paradigm
    • Shah NP. 2006. Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Cancer Chem-other Pharmacol, 58(Suppl 7):49-53.
    • (2006) Cancer Chem-other Pharmacol , vol.58 , Issue.7 SUPPL. , pp. 49-53
    • Shah, N.P.1
  • 44
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • Shah NP, Nicoll JM, Nagar B, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2:117-25.
    • (2002) Cancer Cell , vol.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3
  • 45
    • 33846228789 scopus 로고    scopus 로고
    • Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia
    • Soverini S, Colarossi S, Gnani, et al. 2006. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res, 12:7374-9.
    • (2006) Clin Cancer Res , vol.12 , pp. 7374-7379
    • Soverini, S.1    Colarossi, S.2    Gnani3
  • 46
    • 23044458596 scopus 로고    scopus 로고
    • ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia
    • Soverini S, Martinelli G, Rosti, et al. 2005. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol, 23:4100-9.
    • (2005) J Clin Oncol , vol.23 , pp. 4100-4109
    • Soverini, S.1    Martinelli, G.2    Rosti3
  • 47
    • 33745102555 scopus 로고    scopus 로고
    • Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
    • Talpaz M, Shah NP, Kantarjian H, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354:2531-41.
    • (2006) N Engl J Med , vol.354 , pp. 2531-2541
    • Talpaz, M.1    Shah, N.P.2    Kantarjian, H.3
  • 48
    • 24644464172 scopus 로고    scopus 로고
    • AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
    • Verstovsek S, Golemovic M, Kantarjian H, et al. 2005. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer, 104:1230-6.
    • (2005) Cancer , vol.104 , pp. 1230-1236
    • Verstovsek, S.1    Golemovic, M.2    Kantarjian, H.3
  • 49
    • 33745114173 scopus 로고    scopus 로고
    • AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL
    • Weisberg E, Manley P, Mestan J, et al. 2006. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer, 94:1765-9.
    • (2006) Br J Cancer , vol.94 , pp. 1765-1769
    • Weisberg, E.1    Manley, P.2    Mestan, J.3
  • 50
    • 33745085275 scopus 로고    scopus 로고
    • OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilo-tinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
    • White DL, Saunders VA, Dang P, et al. 2006. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilo-tinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108:697-704.
    • (2006) Blood , vol.108 , pp. 697-704
    • White, D.L.1    Saunders, V.A.2    Dang, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.